App-Quantinova.ai

Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates in 72 patients, a report from a district general hospital

P Radhakrishnan - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

Oraprine

A service evaluation of pre-operative nutritional optimisation in patients with Crohn’s disease using exclusive enteral nutrition with or without supplementary parenteral nutrition

D O'Hanlon - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

Hydroxyzine

Real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive ulcerative colitis patients: Results from the EVOLVE study

A Yarur - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

Entyvio

IBD patients should be stratified to guide out-of-hospital monitoring: ICHOM-derived outcomes from a dedicated IBD telephone clinic

R K Fofaria - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Infliximab induction regimes in steroid refractory acute severe colitis: a multi-centre retrospective cohort study with propensity score analysis

S Sebastian - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

Infliximab

High incidence of hyperglycaemia in steroid treated hospitalised inflammatory bowel disease (IBD) patients and its risk factors identified by machine learning methods

M McDonnell - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Inflammatory bowel disease

Hydrocortisone

Comparative effectiveness of vedolizumab and ustekinumab as induction therapy in anti-TNF refractory Crohn’s disease: a multi-centre retrospective cohort study

T Townsend - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

Entyvio

Ustekinumab in resistant Crohn’s disease: 1-year UK IBD tertiary referral centre ‘real-world’ experience

S P Borg-Bartolo - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

Ustekinumab

An interim analysis of real-world safety data from an ongoing, non-interventional, observational study of patients with inflammatory bowel disease treated with CT-P13, an infliximab biosimilar, in the context of usual care with reference infliximab

B Bokemeyer - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

Infliximab Biosimilar

Post-marketing safety experience of vedolizumab in patients receiving concomitant treatment with other biologics

R D Cohen - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Entyvio

Development of an inflammatory bowel disease-specific nutrition screening tool (IBD-NST)

C Wall - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

Discordance in patient and physician perspectives and priorities in communication and management of ulcerative colitis: results of the European ulcerative colitis narrative survey

L Peyrin-Biroulet - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

N/A

CD-TREAT a novel dietary therapy of active Crohn’s disease using the exclusive enteral nutrition paradigm

V Svolos - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

N/A

How acceptable is a ‘treat to target’ (T2T) approach to IBD patients in clinical remission?

J Carbonell - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Depression

N/A

Risk of cancer in paediatric onset inflammatory bowel disease: a nationwide cohort study 1977–2014

V S Kjrgaard - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

The cost burden of Crohn’s disease and ulcerative colitis dependent on biologic treatment status – a register-based Danish population study from 2003 to 2015

S Alulis - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

A significant decline in surgical resections during childhood with increased prevalence of anti-TNF therapy in patients with paediatric inflammatory bowel disease

J J Ashton - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

The progression of inflammatory bowel disease throughout Latin America: a systematic review

P Kotze - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

Mesalamine

Extra intestinal manifestations and other comorbidities in Crohn’s disease and Ulcerative colitis are equally likely to appear before IBD diagnosis: a Danish nationwide registry study from 2003 to 2015

K Vadstrup - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

Medical treatment and surgery in patients with elderly-onset inflammatory bowel disease: 3-year follow-up of Epi-IBD 2010–2011 cohorts

V Hernandez - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

Filters

45280 Abstracts